Interview with Jenny Winter, Managing Director, AstraZeneca Hungary
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Address: 1113 Budapest, Bocskai út 134-146. Hungary,Hungary
Tel: +36 1 883 6500
Web: http://www.astrazeneca.hu/
We are active in over 100 countries with a growing presence in emerging markets including China, Brazil, Mexico and Russia.
We employ over 61,000 people (46% in Europe, 24% in the North America, 7% in Latin America and 24% in Asia, Africa and Australasia).
We invest over $4 billion in R&D each year. Around 15,7001 people work in our R&D organisation and we have 14 major R&D centres in eight countries, including Sweden, the US and the UK.
We have 9,300 employees at 23 supply and manufacturing sites in 16 countries.
In 2010, our worldwide sales totalled over $33 billion (including 10 medicines with sales of over $1 billion each).
Alongside our commitment to competitiveness and performance, we continue to be led by our core values to deliver business success responsibly. We are positioned in the top 8% in the sector in the Dow Jones World and STOXX (European) Sustainability Indexes.
We focus our skills and resources on six important areas of healthcare, which include some of the world’s most serious illnesses:
– Cardiovascular
– Gastrointestinal
– Infection
– Neuroscience
– Oncology
– Respiratory
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
MD Pál Szamosújvari, Judit Jávor, Pál Szamosújvari Jr—Founder, R&D Director, and Director of Pharma Patent respectively—share their insights on the activities of the company, the importance of R&D, the challenges…
Csilla Léka, general manager of Global Clinical Trials in Hungary shares her insights on the portfolio of the company, the most prevalent therapeutic areas, the developments in clinical trials over…
Calin Galaseanu, recently appointed general manager of Novo Nordisk Hungary, elaborates on the country’s strong treatment paradigm for diabetes. He goes on to highlight Hungary’s key positioning as a strategic…
László Dene, managing director of Bellis, gives his insights on the trends affecting the wholesale supply chain and product delivery in Hungary, the strategic positioning of the company as the…
Gergely Jánoki CEO of Medi-Radiopharma shares his insights on the activities of the company, the trends in the radiopharmaceutical industry while highlighting regulatory trends, the importance of quality, the driving…
Dr Antal Feller, CEO of Hungaropharma, gives his insights on the pharma trends affecting the wholesale supply chain and product delivery in Hungary, the strategic positioning of the company, on…
Francesco Banchi, general manager of Boehringer Ingelheim Hungary, elaborates on the successful development of the affiliate in recent years, making progress in new product reimbursement. As an experienced leader in…
Dr. Bodoky Gyorgy, founder and Honorary President of the Hungarian Society of Clinical Oncology (MKOT), explains the activities of the society, the multi-stakeholder collaborations MKOT has, the challenges of oncological…
Péter Ferdinandy and Zsuzsanna Helyes, President and Secretary General of the Hungarian Society for Experimental and Clinical Pharmacology (HUPHAR), share their insights about the role of the society, the R&D…
József Béres, President of Béres and Ferenc Major, CEO, share their insights on the history of the company, its performance and approach to creating brand awareness, the importance of R&D…
Dr. András Szabó, CEO of Szinapszis, a Hungarian market research and consulting agency specialized in the health industry, offers his expert insights on the key challenges and trends shaping the…
After years of planning and collaboration with various stakeholders, in 2017 the Hungarian government launched the Electronic Health Service Area (EESZT): a centralized database of patient records and health interventions…
See our Cookie Privacy Policy Here